Alex Dorsch – CEO & Managing Director – Chalice Mining (ASX:CHN) is advancing the Gonneville Project—a major 2020 discovery in Western Australia with critical metals like platinum, nickel, and copper—towards development. The project boasts a tier-1 Mineral Resource Estimate, significant land in the new West Yilgarn Ni-Cu-PGE Province, and has earned multiple awards, including the 2023 Thayer Lindsley Award.
Copyright 2024 – Finance News Network
21 Mar 2022 - Austco Healthcare Limited (ASX:AHC) CEO Clayton Astles provides an overview of the company, discussing technology and products, supply chain management, revenue and outlook.
19 May 2023 - CODA Minerals Limited (ASX:COD) CEO and Executive Director Chris Stevens provides an overview of the company, discussing early successes, scoping study results and timeline.
31 Jan 2020 - Los Cerros Limited (ASX:LCL) Managing Director, Jason Stirbinskis, talks about the company's gold projects in Colombia, the potential for high grade porphyry despots and plans to advance drilling at its Chuscal target.
10 Oct 2023 - Andrew Worland - Managing Director and Chief Executive Officer - International Graphite (ASX:IG6) is building Australia’s capability in critical battery minerals and establishing a new ethical supply of battery anode graphite to support the global revolution in clean energy.
21 Jun 2021 - BluGlass Limited (ASX:BLG) Executive Chair, James Walker and Chief Technology and Operations Officer, Dr Ian Mann discuss the company's laser diode production and its recent rights issue.
23 Sep 2019 - SUDA Pharmaceuticals Limited (ASX:SUD) Managing Director & CEO, Stephen Carter discusses the company's portfolio and the benefits of reformulating and delivering medication through the oral mucosa.
26 Apr 2021 - Praemium Limited (ASX:PPS) CEO and Managing Director Michael Ohanessian talks about the company's strong 1H21 results, the successful acquisition of Powerwrap, platform enhancements and outlook.
25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.
